Theravance Biopharma's blood pressure drug fails to meet main goal in late-stage trial
03/03/2026 13:35
March 3 (Reuters) - Theravance Biopharma TBPH.O said on Tuesday its experimental drug to treat a type of blood pressure disorder failed to meet the main goal in a late-stage study. (Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Krishna Chandra Eluri) ((Padmanabhan.Ananthan@thomsonreuters.com;))
Recent news on Theravance Biopharma
See all newsIreland's Theravance Biopharma Q1 revenue beats estimates on YUPELRI growth
Ireland's Theravance Biopharma Q4 revenue misses expectations
Corrected: BRIEF-Theravance Biopharma Q4 Operating Income USD 20.012 Million
U.S. STOCKS ON THE MOVE-Versant Media Group, Lithium miners, Expedia Group
U.S. STOCKS ON THE MOVE-Expedia Group, Blue Owl Capital, Enphase Energy